Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NABPLAGEM vs. Nab-paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Cancer
NCT06783140Phase 3Active, not recruiting
- Sponsor
- University Health Network
- Start
- Jun 2025
- Primary completion
- Jun 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Cisplatin micelle injection (HA132) in pancreatic adenocarcinoma (PDAC), sponsored by University Health Network. Started Jun 2025; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06783140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783140.